LWA
SRPT icon

Lenox Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Lenox Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10
Closed -$1K – 970
2021
Q4 		$1K Buy
+10
New +$855 ﹤0.01% 907
2019
Q2 		– Sell
-49
Closed -$6K – 562
2019
Q1 		$6K Buy
+49
New +$6.3K ﹤0.01% 339

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lenox Wealth Advisors's SRPT Position: Q1 2022 in Review

Lenox Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 10 shares — an estimated $1K sold.

Lenox Wealth Advisors first reported a position in SRPT in Q1 2019 and held it in 2 quarters. The position peaked at $6K in Q1 2019. 328 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

  • Lenox Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Lenox Wealth Advisors sold 10 Sarepta Therapeutics shares in Q1 2022, an estimated $1K.
  • Lenox Wealth Advisors first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 2 quarters.
  • Lenox Wealth Advisors's Sarepta Therapeutics position peaked at $6K in Q1 2019.
  • 328 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.